Amphastar Pharmaceuticals (AMPH) FY2017 results: revenue $240 million, down 5.9% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $240 million for fiscal 2017, the year ended 31 December 2017, down 5.9% on the year before. Net income was $4 million, down 62.9%, and diluted earnings per share $0.09. The figures are the company's own, from the 10-K it filed with the SEC on 15 March 2019.
Revenue
$240 million
-5.9% on the year
FY2012FY2017
Operating margin
-0.5%
6.0% a year earlier
FY2012FY2017
Net income
$4 million
-62.9% on the year
FY2012FY2017
Diluted EPS
$0.09
-57.1% on the year
FY2012FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
240
255
252
-5.9%
Cost of revenue
149
151
174
-1.1%
Gross profit
90.5
104
77.3
-13.1%
Gross margin
37.7%
40.8%
30.8%
Research and development
43.5
41.5
37.3
+4.8%
Operating income
-1.3
15.4
-6.9
Operating margin
-0.5%
6.0%
-2.7%
Interest expense
0.8
1.0
1.0
-19.3%
Pre-tax income
1.2
14.6
-10.4
-91.5%
Income tax
-2.4
4.8
-7.6
Effective tax rate
-192.0%
32.9%
n/a
Net income
3.6
9.8
-2.8
-62.9%
Net margin
1.5%
3.8%
-1.1%
Diluted EPS
$0.09
$0.21
-$0.06
-57.1%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
39.2
38.6
10.7
+1.7%
Capital expenditure
35.1
21.4
16.0
+64.2%
Free cash flow
4.1
17.2
-5.3
-76.1%
Free cash flow margin
1.7%
6.7%
-2.1%
Cash from investing
-36.9
-39.5
-16.9
Cash from financing
-7.7
7.1
2.2
Depreciation and amortisation
6.4
14.7
13.3
-56.3%
Share-based compensation
17.1
15.1
12.8
+13.0%
Buybacks
30.7
9.9
9.9
+210.3%
Diluted shares, weighted
48m
48m
45m
+1.8%
Shares outstanding at period end
47m
46m
45m
+0.8%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
334
329
296
+1.4%
Debt
45.7
36.0
40.3
+26.9%
Other liabilities
71.6
62.5
54.3
+14.7%
Total liabilities and equity
451
428
390
+5.5%
Fixed assets
181
153
142
+18.0%
Goodwill
4.5
4.0
3.7
+12.2%
Intangible assets
11.5
17.1
7.0
-33.0%
Investments
2.6
0.5
n/a
+400.0%
Cash and equivalents
65.6
72.4
66.1
-9.3%
Receivables
36.0
26.8
33.2
+34.4%
Inventory
63.6
79.8
70.7
-20.2%
Other assets
86.8
74.3
67.3
+16.8%
Total assets
451
428
390
+5.5%
10-K for the year ended 31 December 2017, filed 15 March 2019: the filing.